News
NICE backs AZ’ Calquence for chronic lymphocytic leukaemia
The National Institute for Health and Care Excellence has published preliminary guidelines backing use of AstraZeneca’s Calquence (acalabrutinib) as an NHS funded treatment for chronic lymphocytic leukaemia (CLL).